ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has announced two new leadership appointments to its Asia Pacific operations. Mary Pan has been appointed vice president, Asia Pacific, where she will lead ICON’s continued growth and expansion in the region. Hiroshi Ichikawa has been appointed vice president and general manager of ICON’s operations in Japan.
Pan brings to ICON over 15 years of global pharmaceutical and clinical development expertise with a strong track record in Asia. Pan joins ICON from Becton Dickinson, a medical technology company, where she was head of strategy and innovation in Asia. Prior to that Pan was managing director, Asia-Pacific, for ClinTec International. Pan also has held senior medical affairs and clinical development roles in Crucell (Johnson & Johnson) and Pfizer.
Ichikawa joins ICON with 30 years of CRO and pharmaceutical industry experience in Japan. Prior to ICON, Ichikawa was executive vice president and senior director of the regulatory science department at A2Healthcare, an ITOCHU company. Ichikawa also was president and CEO of Asklep following its acquisition of PPCJ, a CRO he founded in 2008. Ichikawa also spent 16 years in leadership positions with CMIC Japan and was project leader for the clinical development division of Sankyo.
ICON provides a full range of clinical development services to support global and pan-Asian trials. ICON operates from 22 offices in Asia-Pacific and employs over 2,600 professionals in the region. ICON’s presence and capabilities in Japan, in particular in oncology, were strengthened in 2014 through the acquisition of Aptiv Solutions, which included Japanese CRO, Niphix.